http://orcid.org/0000-0003-4624-4599
References
- Stokes JR, Casal TB. The use of Anti-IgE therapy beyond allergic asthma. J Allergy Clin Immunol Pract. 2015;3:162–6.
- Bavbek S, Aydın O, Ozdemir SK, Yılmaz I, Celik GE, Demirel YS, et al. Therapy with omalizumab in patients with severe persistent allergic asthma: A real life data in Turkey. Tuberk Toraks 2010;58:425–434
- Aydın O, Sozener ZC, Soyyiğit S, Kendirlinan R, Gençtürk Z, Mısırlıgil Z, et al. Omalizumab in the treatment of allergic bronchopulmonary aspergillosis: one center's experience with 14 cases. Allergy Asthma Proc 2015;36(6):493–500.
- European Network for Understanding Mechanisms of Severe Asthma. The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. Eur Respir J 2003;22:470–7
- Humbert M, Durham SR, Ying S, Kimmitt P, Barkans J, Assoufi B, et al. IL-4 and IL-5 mRNA and protein in bronchial biopsies from patients with atopic and nonatopic asthma: evidence against “intrinsic” asthma being a distinct immunopathologic entity. Am J Respir Crit Care Med. 1996;154(5):1497–1504.
- Menzella F, Piro R, Facciolongo N, Castagnetti C, Simonazzi A, Zucchi L. Long-term benefits of omalizumab in a patient with severe non-allergic asthma. Allergy Asthma Clin Immunol. 2011;7(1):9. https://doi.org/10.1186/1710-1492-7-9
- Van den Berge M, Pauw RG, De Monchy JG, van Minnen CA, Postma DS, Kerstjens HA. Beneficial effects of treatment with anti-IgE antibodies (Omalizumab) in a patient with severe asthma and negative skin-prick test results. Chest. 2011;139(1):190–3.
- De Llano LP, Vennera Mdel C, Álvarez FJ, Medina JF, Borderías L, Pellicer C, et al. Spanish Registry. Effects of omalizumab in non-atopic asthma: results from a Spanish multicenter registry. J Asthma. 2013;50(3):296–301.
- Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A et al. Series ATS/ERS Task force: Standardisation of lung function testing. Eur Respir J. 2005;26:319–38
- Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention updated 2015. Available from: http://www.ginaasthma.org [last accessed 12 August 2015].
- Bousquet J, Siergiejko Z, Swiebocka E, Humbert M, Rabe KF, Smith N et al. Persistency of response to omalizumab therapy in severe allergic (IgE-mediated) asthma. Allergy. 2011;66(5):671–8
- Lieberman P, Patterson R, Kunske R. Complications of long-term steroid therapy for asthma. J Allergy Clin Immunol 1972;49:329–36
- Domingo C, Pomares X, Angrill N, Rudi N, Amengual M, Mirapeix RM. Effectiveness of omalizumab in non-allergic severe asthma. J Biol Regul Homeost Agents. 2013;27(1):45–53.
- Barnes N, Menzies-Gow A, Mansur AH, Spencer D, Percival F, Radwan A et al. Effectiveness of omalizumab in severe allergic asthma: a retrospective UK real-world study. J Asthma. 2013;50(5):529–36.
- Chanez P, Contin-Bordes C, Garcia G, Verkindre C, Didier A, De Blay F, et al. Omalizumab induced decrease of Fc ´ RI expression in patients with severe allergic asthma. Respir Med. 2010;104 (11):1608–17
- Garcia G, Magnan A, Chiron R, Contin-Bordes C, Berger P, Taillé C, et al. A proof-of-concept, randomized, controlled trial of omalizumab in patients with severe, difficult-to-control, nonatopic asthma. Chest 2013;144:411–9.
- Pillai P, Chan YC, Wu SY, Ohm-Laursen L, Thomas C, Durham SR et al. Omalizumab reduces bronchial mucosal IgE and improves lung function in non-atopic asthma. Eur Respir J 2016;48:1593–1601